Remove 2018 Remove Diabetes Remove Healthcare Professional Remove Patients
article thumbnail

Development of a Multidisciplinary Clinic for the Treatment of Obesity in a Canadian University Family Medicine Group (U-FMG) [Obesity, exercise and nutrition]

Annals of Family Medicine

Context In 2018, 63.1% of Canadians were at greater risk of chronic diseases due to their BMI, including type 2 diabetes, atherosclerosis, and hypertension. Population Studied Patients with obesity enrolled in the Méta-Santé clinic.

DO 130
article thumbnail

Diabetes in Late Life: Nadine Carter, Tamryn Gray, Alex Lee

GeriPal

Summary Transcript Summary Diabetes is common. When I’m on palliative care consults and attending in our hospice unit we have to counsel patients about deprescribing and de-intensifying diabetes medications. And yet we’re also in a different place in diabetes monitoring and management. Goldilocks zone).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Time for Geriatric Assessments in Cancer Care: William Dale, Mazie Tsang, and John Simmons

GeriPal

Does it improve outcomes that patients, caregivers, and clinicians care about? hint: 80% can be done in advance by patients or caregivers) Why is it that some oncologists are resistant to conducting a geriatric assessment, yet have no problem ordering tests that cost thousands of dollars? Welcome back, William. William: Thanks so much.

article thumbnail

How to Make an Alzheimer’s Diagnosis in Primary Care: A Podcast with Nathaniel Chin

GeriPal

That screening influences kind of further treatment, actually, probably more importantly, patient outcomes. And when I asked the patient, well, what happened, the test was sprung on them. Well, even for somebody like you, who’s pretty familiar with the instruments, it might cause distress for the patient, maybe their family.

article thumbnail

Amyloid Antibodies and the Role of the Geriatrician: Nate Chin, Sharon Brangman, and Jason Karlawish

GeriPal

However, as noted in our editorial published with the donanemab trial , the modest benefits of amyloid antibodies would likely not be questioned by patients, clinicians, or payers if amyloid antibodies were low risk, inexpensive, and simple to administer. The patients continued to be followed. However, they are none of these.